Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology

Journal of the National Comprehensive Cancer Network 2026

View at publisher
Authors: Susan M. Swetter, Douglas Johnson, Mark R. Albertini, Christopher A. Barker, Sarah Bateni, Joel Baumgartner, Shailender Bhatia, Christopher Bichakjian, Genevieve Boland, Sunandana Chandra, David Chen, Bartosz Chmielowski
+30 more Jacob Choi, Dominick DiMaio, Roxana Dronca, Martin D. Fleming, Anjela Galan, Samantha Guild, Siwen Hu‐Lieskovan, Giorgos Constantine Karakousis, Kari Kendra, Maija Kiuru, Julie R. Lange, Ryan Lanning, Theodore Logan, Miguel Materin, Kelly C. Nelson, Daniel Olson, Anthony J. Olszanski, P A Ott, Igor Puzanov, Luke Rothermel, April K. Salama, Adrienne Shannon, Rohit Sharma, Arun Singh, Andrew Stacey, Katy K. Tsai, Evan John Wuthrick, Yan Xing, Nicole R. McMillian, Sara Espinosa
DOI: 10.6004/jnccn.2026.0027
Cited by: 1
References: 160

Abstract

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.

Fields of Study & Subjects

Cutaneous Melanoma Detection and Management Melanoma and MAPK Pathways Nonmelanoma Skin Cancer Studies

Publication details

Journal / source
Journal of the National Comprehensive Cancer Network
Publisher
Harborside Press, LLC
Volume
24
Issue
6
Pages
272–277
Publication date
1 June 2026
Language
EN